Deferasirox (ICL670)
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Overload
Conditions
Iron Overload, Hereditary Hemochromatosis
Trial Timeline
Aug 1, 2006 → Mar 1, 2009
NCT ID
NCT00395629About Deferasirox (ICL670)
Deferasirox (ICL670) is a phase 1/2 stage product being developed by Novartis for Iron Overload. The current trial status is completed. This product is registered under clinical trial identifier NCT00395629. Target conditions include Iron Overload, Hereditary Hemochromatosis.
What happened to similar drugs?
5 of 13 similar drugs in Iron Overload were approved
Approved (5) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00631163 | Phase 2 | Completed |
| NCT00395629 | Phase 1/2 | Completed |
Competing Products
20 competing products in Iron Overload
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| H. pylori treatment | Eisai | Phase 2/3 | 38 |
| Deferasirox | Novartis | Phase 3 | 40 |
| CSJ137 + Placebo | Novartis | Phase 1 | 29 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 38 |
| Desferasirox | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Approved | 43 |
| ICL670 | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 40 |
| Z-213 | Zeria Pharmaceutical | Phase 3 | 40 |